NRx Pharmaceuticals Future Growth
Future criteria checks 0/6
NRx Pharmaceuticals is forecast to grow earnings at 18.3% per annum. EPS is expected to grow by 34.1% per annum.
Key information
18.3%
Earnings growth rate
34.1%
EPS growth rate
Pharmaceuticals earnings growth | 20.7% |
Revenue growth rate | n/a |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 05 May 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2025 | N/A | -21 | N/A | -26 | 1 |
12/31/2024 | N/A | -21 | N/A | -19 | 2 |
12/31/2023 | N/A | -30 | -22 | -22 | N/A |
9/30/2023 | N/A | -36 | -27 | -27 | N/A |
6/30/2023 | N/A | -39 | -28 | -28 | N/A |
3/31/2023 | N/A | -37 | -35 | -35 | N/A |
12/31/2022 | N/A | -40 | -40 | -40 | N/A |
9/30/2022 | N/A | -60 | -43 | -43 | N/A |
6/30/2022 | N/A | -88 | -48 | -48 | N/A |
3/31/2022 | N/A | -81 | -45 | -45 | N/A |
12/31/2021 | N/A | -93 | -38 | -38 | N/A |
9/30/2021 | N/A | -108 | -27 | -27 | N/A |
6/30/2021 | N/A | -76 | -16 | -16 | N/A |
3/31/2021 | N/A | -76 | -4 | -4 | N/A |
12/31/2020 | N/A | -52 | -2 | -2 | N/A |
9/30/2020 | N/A | -8 | -3 | -3 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: B1Q is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: B1Q is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: B1Q is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if B1Q's revenue is forecast to grow faster than the German market.
High Growth Revenue: B1Q is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if B1Q's Return on Equity is forecast to be high in 3 years time